Potential Oral Treatment Shows Promise in Early Study in Volunteers, Neuropore Says

Potential Oral Treatment Shows Promise in Early Study in Volunteers, Neuropore Says
A potential oral therapy for Parkinson’s disease and amyotrophic lateral sclerosis (ALS) was seen to be safe and well-tolerated at various doses in a Phase 1 trial in healthy volunteers, its developer, Neuropore Therapies, announced. Steps are now underway to allow NPT520-34 to be evaluated in patients, the company said in a press release. NPT520-34 is a small molecule that, in different ... read more
Source: Parkinson’s News TodayPublished on 2020-01-16By Joana Carvalho, MSc